Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$52 Mln
Revenue (TTM)
$4 Mln
Net Profit (TTM)
$-19 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.8
Industry P/E
--
EV/EBITDA
-2.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
147,372,131
CFO
$-159.49 Mln
EBITDA
$-235.03 Mln
Net Profit
$-261.37 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immutep - ADR
| -87.4 | -87.1 | -87.4 | -79.6 | -40.1 | -35.1 | -19.4 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Immutep - ADR
| 31.8 | -9.5 | 37.1 | -46.6 | 4.5 | 75.4 | -2.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immutep - ADR
|
0.4 | 51.6 | 5.0 | -61.4 | -1,706.4 | -36.9 | -- | 0.8 |
| 3.4 | 311.8 | 73.2 | -67.8 | -55.3 | -65.5 | -- | 4.1 | |
| 20.9 | 1,088.5 | 0.5 | -147.4 | -29,734.7 | -150.3 | -- | 6.4 | |
| 29.4 | 1,904.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.2 | 0.5 | |
| 15.4 | 2,582.6 | 550.0 | 458.1 | -3.3 | 45.9 | 5.4 | 1.9 | |
| 14.8 | 1,937.0 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.2 | |
| 16.6 | 1,115.4 | 321.1 | 2.4 | 1,727.2 | 1.1 | 400.3 | 3.9 | |
| 3.3 | 568.7 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.3 | |
| 6.0 | 913.1 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 7.4 | |
| 20.6 | 2,015.9 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 2.8 |
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble... LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. Address: Australia Square, Sydney, NSW, Australia, 2000 Read more
CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
Headquarters
Sydney, NSW
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Immutep Limited - ADR is $0.36 (NASDAQ) as of 02-Apr-2026 13:35 EDT. Immutep Limited - ADR has given a return of -40.07% in the last 3 years.
Since, TTM earnings of Immutep Limited - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Immutep Limited - ADR are Rs 3.53 and Rs 0.34 as of 03-Apr-2026.
Immutep Limited - ADR has a market capitalisation of $ 52 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Immutep Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.